• All Courts
  • Federal Courts
  • Bankruptcies
  • PTAB
  • ITC
Track Search
Export
Download All
Active Filters
Displaying 729-743 of 1,261 results

1098 Exhibit: Exhibit 1098 Garber 2011a

Document IPR2023-00724, No. 1098 Exhibit - Exhibit 1098 Garber 2011a (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

2102 Exhibit: EX2102 Marso, SP, et al, Supplementary Appendix to Semaglutide a...

Document IPR2023-00724, No. 2102 Exhibit - EX2102 Marso, SP, et al, Supplementary Appendix to Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes, N Engl J Med, 3751834 1...

cite Cite Document
Analyze

2436 Exhibit: EX2436 Tanzeum® Prescribing Information rev Dec 2017

Document IPR2023-00724, No. 2436 Exhibit - EX2436 Tanzeum® Prescribing Information rev Dec 2017 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2090 Exhibit: EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes...

Document IPR2023-00724, No. 2090 Exhibit - EX2090 Cosentino, F et al, ESC Guidelines on diabetes, pre diabetes, and cardiovascular diseases developed in collaboration with the EASD, Eur Heart J, 41...

cite Cite Document
Analyze

2460 Exhibit: EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036

Document IPR2023-00724, No. 2460 Exhibit - EX2460 US Food Drug Administration, DrugsFDA, Xultophy 10036 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2466 Exhibit: EX2466 Steglujan Prescribing Information rev Feb 2018

Document IPR2023-00724, No. 2466 Exhibit - EX2466 Steglujan Prescribing Information rev Feb 2018 (P.T.A.B. Jan. 17, 2024)

cite Cite Document
Analyze

2084 Exhibit: EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly...

Document IPR2023-00724, No. 2084 Exhibit - EX2084 R Pratley et al, “Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes SUSTAIN 7 a randomized, open label, phase 3b trial,” La...

cite Cite Document
Analyze

3004 Exhibit: Ex 3004 Attorney Correspondence

Document IPR2023-00724, No. 3004 Exhibit - Ex 3004 Attorney Correspondence (P.T.A.B. Jun. 18, 2024)

cite Cite Document
Analyze

1175 Exhibit: Exhibit 1175 FDA FAQ

Document IPR2023-00724, No. 1175 Exhibit - Exhibit 1175 FDA FAQ (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1197 Exhibit: Exhibit 1197 US10376652

Document IPR2023-00724, No. 1197 Exhibit - Exhibit 1197 US10376652 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1187 Exhibit: Exhibit 1187 US8579869

Document IPR2023-00724, No. 1187 Exhibit - Exhibit 1187 US8579869 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1114 Exhibit: Exhibit 1114 Buse

Document IPR2023-00724, No. 1114 Exhibit - Exhibit 1114 Buse (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1189 Exhibit: Exhibit 1189 Gilbert

Document IPR2023-00724, No. 1189 Exhibit - Exhibit 1189 Gilbert (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1194 Exhibit: Exhibit 1194 US8920383

Document IPR2023-00724, No. 1194 Exhibit - Exhibit 1194 US8920383 (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze

1303 Exhibit: Exhibit 1303 Spiegel CV

Document IPR2023-00724, No. 1303 Exhibit - Exhibit 1303 Spiegel CV (P.T.A.B. May. 22, 2024)

cite Cite Document
Analyze
<< 1 2 3 4 5 ... 49 50 51 52 53 ... >>